-- Medicines Co. Settles Patent Suit With APP Over Generic Copy of Angiomax
-- B y   P h i l   M i l f o r d
-- 2012-01-23T17:51:27Z
-- http://www.bloomberg.com/news/2012-01-23/medicines-co-fresenius-s-app-settle-patent-suits-over-generic-angiomax.html
Medicines Co. (MDCO)  and  Fresenius (FRE) ’s  APP
Pharmaceuticals Inc. (APPX)  settled litigation over patents for the
Angiomax anticoagulant drug, with Medicines agreeing to pay
$30 million to license some APP drugs.  Medicines Co., based in Parsippany, New Jersey, sued
Schaumburg, Illinois-based APP in October 2009 IN Wilmington,
Delaware, federal court alleging patent infringement for plans
to market a generic copy of Angiomax. APP announced the
settlement today.  “The settlement agreement includes a license by The
Medicines Co. to APP” to sell generic Angiomax in the U.S.
starting May 1, 2019, Medicines said in a statement.  Medicines will pay APP $30 million for a non-exclusive
license “to sell 10 specified generic products” to hospitals
and suppliers until Jan. 22, 2022, according to a Medicines
 filing  with the U.S. Securities and Exchange Commission.  The case is The Medicines Co. v. APP Pharmaceuticals, 09-
CV-00752, U.S. District Court, District of  Delaware 
(Wilmington).  To contact the reporter on this story:
Phil Milford in Wilmington, Delaware, at 
 pmilford@bloomberg.net .  To contact the editor responsible for this story:
Michael Hytha at   mhytha@bloomberg.net . 